ATE336508T1 - Kaliumkanalprotein kcnq5, ein ziel für erkrankungen des zentralen nervensystems und herz-gefäss-systems - Google Patents
Kaliumkanalprotein kcnq5, ein ziel für erkrankungen des zentralen nervensystems und herz-gefäss-systemsInfo
- Publication number
- ATE336508T1 ATE336508T1 AT01909831T AT01909831T ATE336508T1 AT E336508 T1 ATE336508 T1 AT E336508T1 AT 01909831 T AT01909831 T AT 01909831T AT 01909831 T AT01909831 T AT 01909831T AT E336508 T1 ATE336508 T1 AT E336508T1
- Authority
- AT
- Austria
- Prior art keywords
- kcnq5
- potassium channel
- activity
- target
- central nervous
- Prior art date
Links
- 101000994656 Homo sapiens Potassium voltage-gated channel subfamily KQT member 5 Proteins 0.000 title abstract 5
- 102100034365 Potassium voltage-gated channel subfamily KQT member 5 Human genes 0.000 title abstract 5
- 102000004257 Potassium Channel Human genes 0.000 title 1
- 210000000748 cardiovascular system Anatomy 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108020001213 potassium channel Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10013732A DE10013732A1 (de) | 2000-03-21 | 2000-03-21 | Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE336508T1 true ATE336508T1 (de) | 2006-09-15 |
Family
ID=7635606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01909831T ATE336508T1 (de) | 2000-03-21 | 2001-03-13 | Kaliumkanalprotein kcnq5, ein ziel für erkrankungen des zentralen nervensystems und herz-gefäss-systems |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1268545B1 (de) |
| JP (1) | JP5622345B2 (de) |
| AT (1) | ATE336508T1 (de) |
| AU (1) | AU2001237438A1 (de) |
| DE (2) | DE10013732A1 (de) |
| WO (1) | WO2001070811A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2369822A1 (en) * | 1999-04-14 | 2000-10-19 | Merck & Co., Inc. | Novel human voltage-gated potassium channel |
| US6649371B1 (en) | 1999-06-11 | 2003-11-18 | Neurosearch A/S | Potassium channel KCNQ5 and sequences encoding the same |
| AU2001263486A1 (en) * | 2000-05-26 | 2001-12-11 | Bristol-Myers Squibb Company | Human KCNQ5 potassium channel, methods and compositions thereof |
| DE10342022A1 (de) | 2003-09-11 | 2005-04-07 | Voith Paper Patent Gmbh | Aufwickelvorrichtung |
| US7517960B2 (en) | 2006-01-19 | 2009-04-14 | Wyeth | Rat KCNQ5 voltage-gated potassium channel |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1007638B1 (de) * | 1997-08-12 | 2007-03-07 | Bristol-Myers Squibb Company | Kcnq kaliumkanäle und verfahren zur deren modulierung |
| JP4520634B2 (ja) * | 1997-10-24 | 2010-08-11 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | 良性の家族性新生児痙攣(bfnc)および他の癲癇において突然変異されたkcnq2およびkcnq3−カリウムチャンネル遺伝子 |
| GB9726339D0 (en) * | 1997-12-13 | 1998-02-11 | Zeneca Ltd | Human-derived tissue-specific potassium channel |
| DK1147134T3 (da) * | 1999-01-26 | 2007-02-05 | Neurosearch As | Hidtil ukendte kaliumkanaler og gener, der koder for disse kaliumkanaler |
| CA2369822A1 (en) * | 1999-04-14 | 2000-10-19 | Merck & Co., Inc. | Novel human voltage-gated potassium channel |
| WO2000077035A2 (en) * | 1999-06-11 | 2000-12-21 | Neurosearch A/S | Novel potassium channels and genes encoding these potassium channels |
-
2000
- 2000-03-21 DE DE10013732A patent/DE10013732A1/de not_active Withdrawn
-
2001
- 2001-03-13 AU AU2001237438A patent/AU2001237438A1/en not_active Abandoned
- 2001-03-13 WO PCT/EP2001/002791 patent/WO2001070811A1/en not_active Ceased
- 2001-03-13 JP JP2001569011A patent/JP5622345B2/ja not_active Expired - Fee Related
- 2001-03-13 AT AT01909831T patent/ATE336508T1/de not_active IP Right Cessation
- 2001-03-13 EP EP01909831A patent/EP1268545B1/de not_active Expired - Lifetime
- 2001-03-13 DE DE60122301T patent/DE60122301T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004512009A (ja) | 2004-04-22 |
| EP1268545B1 (de) | 2006-08-16 |
| AU2001237438A1 (en) | 2001-10-03 |
| EP1268545A1 (de) | 2003-01-02 |
| DE10013732A1 (de) | 2001-09-27 |
| DE60122301D1 (de) | 2006-09-28 |
| DE60122301T2 (de) | 2007-09-13 |
| JP5622345B2 (ja) | 2014-11-12 |
| WO2001070811A1 (en) | 2001-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL130036A0 (en) | Survivin a protein that inhibits cellular apoptosis and its modulation | |
| AU5753598A (en) | Novel genes coding for amino acid deacetylases with specificity for N-acetyl-L-phosphinothricin, their isolation and use | |
| ATE389666T1 (de) | Hohe expressionsrate von proteinen | |
| ATE227739T1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
| ATE319818T1 (de) | Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren | |
| WO2004053059A3 (en) | Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same | |
| DE69938600D1 (de) | Fusionsproteine und deren verwendung zur messung von protease-aktivität | |
| NZ323795A (en) | Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides | |
| BR9912455A (pt) | ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória | |
| DE60313866D1 (de) | Polypeptide mit alpha-h alpha amino acid amide racemase aktivitität und nukleinsäuren kodierend dafür | |
| ATE311443T1 (de) | Methoden zur durchforstung (screenen) von proteinen | |
| PT907731E (pt) | Receptores gaba[b] metabotropicos, ligandos especificos dos receptores e suas utilizacoes | |
| ATE336508T1 (de) | Kaliumkanalprotein kcnq5, ein ziel für erkrankungen des zentralen nervensystems und herz-gefäss-systems | |
| DE60214867D1 (en) | Histonedeacetylase 9 | |
| DE60128830D1 (de) | Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren | |
| DE69632963D1 (de) | Mch3, eine apoptosis-protease, kodierende nukleinsäuren und methoden zur verwendung | |
| ATE202798T1 (de) | D-aminosäure-oxidase kodierendes dns-fragment | |
| ATE312350T1 (de) | Verfahren zur identifizierung von verbindungen, die die neuronale aktivität modulieren | |
| DE60026569D1 (de) | Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen | |
| DE69838459D1 (de) | Für den licht-überempfinlichkeitsphaenotyp kodierende nukleotidsequenzen von tomaten, dadurch kodierte proteine und deren verwendungen | |
| MXPA03011260A (es) | Receptor acoplado a proteina g y usos del mismo. | |
| ATE213773T1 (de) | In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür | |
| WO1999063081A3 (en) | Ion channels | |
| WO2002068599A3 (en) | Retinoid inducible proteins of vascular smooth muscle cells and uses thereof | |
| WO1999058641A8 (en) | Nt2lp, novel g-protein coupled receptors having homology to neurotensin-2 receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |